利分能配合赛庚啶治疗流行性腮腺炎疗效观察  

Effect observation of association of interferonα-2b with cyproheptadinle in treatment of epidemic parotitis

作　　者：张德生 胡国华[2] 张冬卿 

机构地区：[1]浙江省金华职工中等卫生学校,浙江东阳322100 [2]浙江省金华职业技术学院医学院,浙江金华321000 [3]浙江省东阳市中医院,浙江东阳322100

出　　处：《儿科药学杂志》2005年第2期43-44,共2页Journal of Pediatric Pharmacy

摘　　要：目的:观察利分能(干扰素α鄄2b)、赛庚啶联合治疗小儿流行性腮腺炎的临床疗效。方法:观察组肌肉注射利分能(重组人干扰素α鄄2b)100万单位,每日1次,赛庚啶0.25mg/(kg·次),每日3次口服。对照组利巴韦林10～15mg/kg静脉点滴,每日1次,同时给予板蓝根冲剂10g,每日3次口服,两组疗程均5d。结果:观察组疗效明显优于对照组,各项指标比较均有显著差异(P<0.05)。结论:利分能与赛庚啶联合治疗小儿流行性腮腺炎临床疗效满意。Objective: To study the clinical effect of association of Lifenneng with cyproheptadinle in treatment of children with epidemic parotitis. Methods: The treatment group were given lifenneng 1,000,000 u/d, im. with cyproheptadinle 0.25 mg/(kg.d) tid. po 3 times a day; and the contrast group were given ribavirin 10～15 mg/(kg.d) of injection with Banlangen 10 g 3 times a day. The treatment period for both groups was 5 d. Results: By comparison, the clinical effect of the treatment group is significantly better than the contrast one (P < 0.05). Conclusions: The clinical effect of association of Lifenneng with cyproheptadinle in treatment of children with epidemic parotitis is satisfactory.

关 键 词：利分能(干扰素α-2b) 赛庚啶 流行性腮腺炎 

分 类 号：R979.5[医药卫生—药品] R976[医药卫生—药学]